Fed Circuit rejects Biogen’s plea in MS drug dispute

The US Court of Appeals for the Federal Circuit has affirmed a lower court’s decision which found that Banner Life Sciences wasn’t infringing a Biogen patent with its bioequivalent version of a multiple sclerosis drug.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Appeals court sides with Pfizer, Merck KGaA in $5bn suit

29 September 2020 The US Court of Appeals for the Federal Circuit has sided with EMD Serono and Pfizer over the invalidation of a multiple sclerosis drug patent, in a defeat for biotech company Biogen.

Americas

Fed Circuit affirms generic maker’s win over Eagle

11 May 2020 The US Court of Appeals for the Federal Circuit has affirmed a generic maker’s victory over pharmaceutical company Eagle Pharmaceuticals in a case involving cancer drug Belrapzo.

Americas

Biogen takes Creative Biolabs to court over antibody

19 March 2020 Biogen and the University of Zurich have accused New York-based Creative Biolabs of unlawfully selling copies of Biogen’s aducanumab antibody.

More features

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation: Follow the money (Part I)

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Former PTAB judge joins Sterne Kessler

Fed Circuit rejects Biogen’s plea in MS drug dispute

More on this story

Editor's picks

Editor's picks

More features